Pharma Industry News

Advancing Development and Manufacturing of Microbiome-Derived Therapeutics (BIO 2024)

1 week ago
Add Comment
by David Miller
946 Views

Aaron Cowley, PhD, chief technical officer and co-founder, Captozyme, discussed the advancement in development of microbiome-derived therapeutics at BIO 20204.

Aaron Cowley, PhD, chief technical officer and co-founder, Captozyme, discussed the advancement in development of microbiome-derived therapeutics at BIO 20204.

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Leave a Comment

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]